Recommendations for Implementing Lung Cancer Screening with Low-Dose Computed Tomography in Europe

Abstract

Lung cancer screening (LCS) with low-dose computed tomography (LDCT) was demonstrated in the National Lung Screening Trial (NLST) to reduce mortality from the disease. European mortality data has recently become available from the Nelson randomised controlled trial, which confirmed lung cancer mortality reductions by 26% in men and 39–61% in women. Recent studies in Europe and the USA also showed positive results in screening workers exposed to asbestos. All European experts attending the “Initiative for European Lung Screening (IELS)”—a large international group of physicians and other experts concerned with lung cancer—agreed that LDCT-LCS should be implemented in Europe. However, the economic impact of LDCT-LCS and guidelines for its effective and safe implementation still need to be formulated. To this purpose, the IELS was asked to prepare recommendations to implement LCS and examine outstanding issues. A subgroup carried out a comprehensive literature review on LDCT-LCS and presented findings at a meeting held in Milan in November 2018. The present recommendations reflect that consensus was reached.

Impact on All-Cause and Cardiovascular Mortality Rates of Coronary Artery Calcifications Detected during Organized, Low-Dose, Computed-Tomography Screening for Lung Cancer: Systematic Literature Review and Meta-Analysis

“…According to the latter, the benefit could be even greater for women, with 39–61% lower lung-cancer-specific mortality. Those findings led the Unites States and numerous other countries to initiate organized lung-cancer-screening programs [ 3 , 4 ].…”

Short-Term Changes in Quality of Life in Patients with Advanced Lung Cancer during In-Hospital Exercise Training and Chemotherapy Treatment: A Randomized Controlled Trial

“…Cancer is currently the second leading cause of death and disability after cardiovascular disease, responsible for around 270,000 deaths annually in Europe [1]. Morbidity and mortality statistics vary widely across the globe.…”

Trends in Participation Rates of the National Cancer Screening Program among Cancer Survivors in Korea

“…This increasing trend has resulted in an increase in cancer prevalence, with 1,867,405 patients as of 1 January 2018 [ 8 ]. In many countries, cancer screening guidelines for the general population exist [ 9 , 10 ]; however, many other countries, including Korea, have no cancer screening guidelines for cancer survivors. In particular, the difference between the cancer screening guideline in Korea versus other countries is that stomach cancer screening is recommended because of the high incidence of stomach cancer in Korea.…”